Tenax Therapeutics, Inc. (TENX)
1.915
+0.06
(+3.51%)
USD |
NASDAQ |
Sep 03, 12:49
Tenax Therapeutics Research and Development Expense (TTM) : 45.26M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 45.26M |
| March 31, 2026 | 38.53M |
| December 31, 2025 | 32.67M |
| September 30, 2025 | 26.73M |
| June 30, 2025 | 19.51M |
| March 31, 2025 | 15.72M |
| December 31, 2024 | 12.71M |
| September 30, 2024 | 9.815M |
| June 30, 2024 | 7.768M |
| March 31, 2024 | 5.639M |
| December 31, 2023 | 3.229M |
| September 30, 2023 | 2.664M |
| June 30, 2023 | 3.139M |
| March 31, 2023 | 4.465M |
| December 31, 2022 | 5.377M |
| September 30, 2022 | 5.158M |
| June 30, 2022 | 4.780M |
| March 31, 2022 | 3.949M |
| December 31, 2021 | 25.15M |
| September 30, 2021 | 25.12M |
| June 30, 2021 | 25.01M |
| March 31, 2021 | 25.59M |
| December 31, 2020 | 4.561M |
| September 30, 2020 | 5.092M |
| June 30, 2020 | 4.956M |
| Date | Value |
|---|---|
| March 31, 2020 | 4.331M |
| December 31, 2019 | 3.471M |
| September 30, 2019 | 2.556M |
| June 30, 2019 | 2.002M |
| March 31, 2019 | 1.664M |
| December 31, 2018 | 1.239M |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | |
| September 30, 2017 | 6.053M |
| June 30, 2017 | 9.033M |
| March 31, 2017 | 11.24M |
| December 31, 2016 | 10.93M |
| September 30, 2016 | 10.31M |
| June 30, 2016 | 8.293M |
| July 31, 2015 | 7.412M |
| April 30, 2015 | 6.627M |
| January 31, 2015 | 5.501M |
| October 31, 2014 | 4.960M |
| July 31, 2014 | 3.150M |
| April 30, 2014 | 2.965M |
| January 31, 2014 | 3.024M |
| October 31, 2013 | 2.716M |
| July 31, 2013 | 2.582M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Manhattan Scientifics, Inc. | -- |
| Exicure, Inc. | 2.029M |
| Century Therapeutics, Inc. | 66.62M |
| Absci Corp. | 86.49M |
| Celularity, Inc. | 9.222M |